{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-077880","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2025-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.168848+00:00","generated_at":"2026-05-20T08:11:48.672216+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bolt Biotherapeutics stockholders approve reverse stock split amendment at 2025 annual meeting","bullets":["Reverse stock split amendment approved: 20,983,236 votes for, 3,224,611 against (86.9% of votes cast).","Laura Berner and Brian O'Callaghan elected as Class I directors with 10.6M and 11.2M votes for, respectively.","PricewaterhouseCoopers LLP ratified as independent auditor for FY2025: 23,330,316 votes for.","Annual meeting had 24,362,318 shares represented out of 38,339,697 entitled to vote."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-077880","json":"https://secwatch.observer/filing/0000950170-25-077880.json","markdown":"https://secwatch.observer/filing/0000950170-25-077880.md","text":"https://secwatch.observer/filing/0000950170-25-077880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000095017025077880/0000950170-25-077880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000095017025077880/bolt-20250527.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T08:11:48.672216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}